Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC cut its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 2.9% in the 3rd quarter, Holdings Channel reports. The firm owned 2,999,935 shares of the biopharmaceutical company’s stock after selling 89,755 shares during the period. Geode Capital Management LLC’s holdings in Dynavax Technologies were worth $33,426,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DVAX. Louisiana State Employees Retirement System boosted its stake in shares of Dynavax Technologies by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock worth $740,000 after acquiring an additional 1,900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 1,172 shares in the last quarter. Peregrine Capital Management LLC raised its holdings in Dynavax Technologies by 1.3% during the 2nd quarter. Peregrine Capital Management LLC now owns 534,454 shares of the biopharmaceutical company’s stock worth $6,002,000 after buying an additional 6,952 shares during the period. Mizuho Markets Americas LLC lifted its stake in Dynavax Technologies by 37.9% during the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock valued at $13,196,000 after buying an additional 323,050 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Dynavax Technologies by 1.8% in the second quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock worth $3,490,000 after buying an additional 5,379 shares during the period. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Stock Up 0.1 %

NASDAQ:DVAX opened at $12.84 on Thursday. The business’s fifty day moving average price is $12.33 and its 200 day moving average price is $11.52. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of 98.78 and a beta of 1.33. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.